Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1007/s40261-020-00907-5

A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

..., Dae Hyun Yoo
28
Clinical Drug Investigation3.20
Volume: 40, Issue: 6, Pages: 541 - 553
Published: Apr 23, 2020
Abstract
The infliximab biosimilar CT-P13 has widely received regulatory approval in all indications of reference infliximab, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). This retrospective analysis investigated drug survival and long-term safety and effectiveness of CT-P13 in patients with RA or AS in the Republic of Korea. This non-interventional, retrospective, multicenter analysis collected medical record data for adult...
Paper Fields
Paper Details
Title
A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
DOI
doi.org/10.1007/s40261-020-00907-5
Published Date
Apr 23, 2020
Journal
Clinical Drug Investigation
Volume
40
Issue
6
Pages
541 - 553
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.